<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03908450</url>
  </required_header>
  <id_info>
    <org_study_id>SI-DN-01</org_study_id>
    <nct_id>NCT03908450</nct_id>
  </id_info>
  <brief_title>Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter</brief_title>
  <acronym>SCBDENOVO</acronym>
  <official_title>Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus
      a paclitaxel coated balloon
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus
      a paclitaxel coated balloon. Prospective, multicenter, randomized, single-blind, 70 patients.
      Experimental intervention: Predilatation of coronary de-novo stenosis followed by a sirolimus
      coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²). Control intervention: Predilatation of
      coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon
      (paclitaxel 3.0 μg/mm²). Follow-up per patient: 30 days telephone call; 6 months angiographic
      + 12 months. clinical follow up

      Key inclusion criteria: &gt; 18 years of age, Clinical evidence of stable or unstable angina or
      a positive functional study, Patients with significant coronary de-novo stenosis (≥ 70%
      diameter stenosis or intermediate ≥ 50% to &lt;70% diameter stenosis with positive functional
      test or symptom of ischemia), Successful lesion preparation (no flow-limiting dissection or a
      residual stenosis &gt; 30%).

      Key exclusion criteria: Acute myocardial infarction within the past 72 hours (STEMI or
      NSTEMI), Intolerance and / or allergy to Sirolimus, Intolerance or allergy to Paclitaxel
      and/or the delivery matrix (main ingredient: iopromide), Patients with an ejection fraction
      of &lt; 30 %, Reference vessel diameter (RVD) &lt; 2.5 mm, Contraindication for whichever necessary
      accompanying medication.

      Primary efficacy endpoint: late lumen loss in-segment at 6 months. Key secondary endpoints:
      Procedural Success: &lt; 30% final diameter stenosis, no flow-limiting dissection (type C or
      higher), TIMI III flow, and the absence of in-hospital MACE. MACE: cardiac death, target
      vessel myocardial infarction, and clinically driven target lesion revascularization
      in-hospital at 6 and at 12 months Individual clinical endpoints at 6 and at 12 months:
      cardiac death, target lesion myocardial infarction, clinically driven target lesion
      revascularization, (stenosis ≥ 50% at follow-up angiography)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Anticipated">August 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>angiographies blinded to treatment groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>late lumen loss in-segment</measure>
    <time_frame>6 months</time_frame>
    <description>angiographic minimal lumen diameter in-segment at 6 months minus minimal lumen diameter at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>in hospital</time_frame>
    <description>&lt; 30% final diameter stenosis, no flow-limiting dissection (type C or higher), TIMI III flow, and the absence of in-hospital MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE MACE</measure>
    <time_frame>at 6 and at 12 months</time_frame>
    <description>cardiac death, target vessel myocardial infarction, and TLR target lesion revascularization in-hospital at 6 and at 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Control intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTCA of coronary de novo lesion PCB</intervention_name>
    <description>PTCA of coronary de novo lesion with drug coated balloon</description>
    <arm_group_label>Control intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTCA of coronary de novo lesion SCB</intervention_name>
    <description>PTCA of coronary de novo lesion with drug coated balloon</description>
    <arm_group_label>Experimental intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical evidence of stable or unstable angina or a positive functional study

          -  Patients with significant coronary de-novo stenosis (≥ 70% diameter stenosis or
             intermediate ≥ 50% to &lt;70% diameter stenosis with positive functional test or symptom
             of ischemia)

          -  Successful lesion preparation (no flow-limiting dissection or a residual stenosis &gt;
             30%)

        Exclusion Criteria:

          -  Acute myocardial infarction within the past 72 hours (STEMI or NSTEMI)

          -  Intolerance and / or allergy to Sirolimus

          -  Intolerance or allergy to Paclitaxel and/or the delivery matrix (main ingredient:

        iopromide)

          -  Patients with an ejection fraction of &lt; 30 %

          -  Reference vessel diameter (RVD) &lt; 2.5 mm

          -  Contraindication for whichever necessary accompanying medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Scheller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical and Experimental Interventional Cardiology, University of Saarland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Scheller, MD</last_name>
    <phone>4968411615927</phone>
    <email>bruno.scheller@uks.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Scheller, MD</last_name>
      <phone>+49 6841 162 3351</phone>
      <email>bruno.scheller@uks.eu</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ali RM, Abdul Kader MASK, Wan Ahmad WA, Ong TK, Liew HB, Omar AF, Mahmood Zuhdi AS, Nuruddin AA, Schnorr B, Scheller B. Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon. JACC Cardiovasc Interv. 2019 Mar 25;12(6):558-566. doi: 10.1016/j.jcin.2018.11.040.</citation>
    <PMID>30898253</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>April 7, 2019</last_update_submitted>
  <last_update_submitted_qc>April 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

